mibefradil has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bin, C; Huan, M; Jing, X; Jun, Y; Kebin, Z; Le, Z; Lingong, Z; Mengya, S; Peilin, L; Shaodong, G; Ying, D; Zihui, X | 1 |
| Chitaley, K; Jiang, X; Luttrell, I; Yang, CC | 1 |
2 other study(ies) available for mibefradil and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Mibefradil reduces hepatic glucose output in HepG2 cells via Ca
Topics: Calcium-Calmodulin-Dependent Protein Kinase Type 2; Diabetes Mellitus, Type 2; Hep G2 Cells; Humans; Mibefradil; Proto-Oncogene Proteins c-akt | 2021 |
T- and L-type voltage-gated calcium channels: their role in diabetic bladder dysfunction.
Topics: Acetylcholine; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Male; Mibefradil; Mice; Mice, Inbred C57BL; Muscle Contraction; Myocytes, Smooth Muscle; Nifedipine; RNA, Messenger; Urinary Bladder; Urinary Bladder Diseases | 2014 |